Working… Menu

POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00234676
Recruitment Status : Completed
First Posted : October 7, 2005
Last Update Posted : January 8, 2008
Wyeth is now a wholly owned subsidiary of Pfizer
Joseph and Rosalyn Newman Foundation
Information provided by:
The Parkinson Study Group

Brief Summary:
The primary objectives of the POETRY study are to assess the safety and tolerability of estrogen replacement therapy (ERT) in postmenopausal women with Parkinson's disease (PD) and to assess recruitment for a study of ERT in postmenopausal women with PD.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: Premarin ® Phase 2

Detailed Description:
POETRY is an 8-week study of 30 post-menopausal women with Parkinson's disease (PD) who will be enrolled at six clinical sites in the United States. The study is designed to measure the safety and tolerability of estrogen replacement therapy (ERT). The study will also measure how ERT affects thinking and behavior, movement and activities of daily living, as well as motor fluctuations and dyskinesias. Although we know there are gender differences in PD, no studies have assessed their impact on symptom management. Women with PD usually require less levodopa, are more likely to experience drug-related dyskinesia, and commonly report changes of their symptoms with menstruation, menopause and use of hormones, implying that hormonal changes may impact PD symptoms. All perimenopausal women face the decision whether or not to use estrogen replacement therapy (ERT) and for women with PD, information about estrogen's effects in PD may facilitate decision-making.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study for the Safety, Tolerability and Efficacy of Estrogen Replacement Therapy (Conjugated Equine Estrogens 0.625 mg Daily) in Post Menopausal Women With Parkinson's Disease
Study Start Date : October 2003
Actual Primary Completion Date : March 2006
Actual Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Drug: Premarin ®
Premarin ® 0.625 mg per day orally

Primary Outcome Measures :
  1. Safety - Adverse event frequency, vital signs (change from Baseline to Month 2) [ Time Frame: 60 days ]
  2. Tolerability - Proportion of participants who complete the trial [ Time Frame: 60 days ]

Secondary Outcome Measures :
  1. Motor [ Time Frame: 60 days ]
  2. Cognition [ Time Frame: 60 days ]
  3. Behavior [ Time Frame: 60 days ]
  4. Serum estradiol levels - change from Baseline to Month 2 [ Time Frame: 60 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Post-menopausal women with Parkinson's disease who experience levodopa-related motor fluctuations averaging at least 2 hours daily in the "off" state confirmed by home diaries
  • Must be on a stable dose of carbidopa/levodopa, immediate or controlled release therapy, antidepressants, or anxiolytics (for the last 30 days)

Exclusion Criteria:

  • Insulin dependent diabetes
  • Thyroid disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00234676

Layout table for location information
United States, California
The Parkinson's Institute
Sunnyvale, California, United States
United States, Georgia
Emory University
Atlanta, Georgia, United States
United States, Indiana
Indiana University School of Medicine
Indianapolis, Indiana, United States
United States, Maryland
University of Maryland
Baltimore, Maryland, United States
United States, New York
University of Rochester
Rochester, New York, United States
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States
Sponsors and Collaborators
The Parkinson Study Group
Wyeth is now a wholly owned subsidiary of Pfizer
Joseph and Rosalyn Newman Foundation
Layout table for investigator information
Principal Investigator: Lisa M Shulman, MD University of Maryland, College Park

Additional Information:
Layout table for additonal information
Responsible Party: Lisa Shulman, MD, Parkinson Study Group Principal Investigator Identifier: NCT00234676     History of Changes
Other Study ID Numbers: POETRY06032003
First Posted: October 7, 2005    Key Record Dates
Last Update Posted: January 8, 2008
Last Verified: December 2007
Keywords provided by The Parkinson Study Group:
Parkinson disease
estrogen replacement therapy
clinical trials
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Estrogens, Conjugated (USP)
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs